Knight Therapeutics Inc. (TSE:GUD - Free Report) - Equities research analysts at Stifel Canada reduced their Q3 2025 EPS estimates for shares of Knight Therapeutics in a research note issued to investors on Thursday, August 7th. Stifel Canada analyst J. Keywood now expects that the company will post earnings of $0.01 per share for the quarter, down from their previous estimate of $0.06. The consensus estimate for Knight Therapeutics' current full-year earnings is $0.10 per share. Stifel Canada also issued estimates for Knight Therapeutics' FY2026 earnings at $0.14 EPS.
Separately, Canaccord Genuity Group set a C$6.50 target price on shares of Knight Therapeutics and gave the company a "buy" rating in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Knight Therapeutics presently has a consensus rating of "Strong Buy" and a consensus price target of C$7.15.
Check Out Our Latest Analysis on GUD
Knight Therapeutics Stock Performance
Shares of TSE:GUD traded down C$0.07 on Monday, hitting C$6.42. 22,270 shares of the company were exchanged, compared to its average volume of 65,325. The company's 50 day moving average price is C$6.04 and its two-hundred day moving average price is C$5.88. Knight Therapeutics has a one year low of C$5.09 and a one year high of C$6.49. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The firm has a market capitalization of C$649.38 million, a price-to-earnings ratio of -21.43, a PEG ratio of -1,013.50 and a beta of 0.50.
About Knight Therapeutics
(
Get Free Report)
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
See Also
Before you consider Knight Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Knight Therapeutics wasn't on the list.
While Knight Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access